Current Report Filing (8-k)
November 18 2020 - 05:17PM
Edgar (US Regulatory)
0001551152 false Common Stock, $0.01 Par
Value ABBV 0001551152 2020-11-18 2020-11-18 0001551152
us-gaap:CommonStockMember exch:XNYS 2020-11-18 2020-11-18
0001551152 exch:XCHI us-gaap:CommonStockMember 2020-11-18
2020-11-18 0001551152 abbv:Sec1.375SeniorNotesDue2024Member
exch:XNYS 2020-11-18 2020-11-18 0001551152
abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2020-11-18
2020-11-18 0001551152 abbv:Sec2.125SeniorNotesDue2028Member
exch:XNYS 2020-11-18 2020-11-18 0001551152
abbv:Sec1.250SeniorNotesDue2031Member exch:XNYS 2020-11-18
2020-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 18, 2020
ABBVIE INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1 North Waukegan Road
North Chicago,
Illinois
60064-6400
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (847)
932-7900
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange
Chicago Stock Exchange
|
|
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
|
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
|
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
|
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On November 18, 2020, AbbVie Inc. issued a press release announcing
the expiration and final results of its offers to exchange any and
all of its outstanding (i) $30,000,000,000 aggregate principal
amount of senior unsecured notes previously issued on November 21,
2019, (ii) $13,251,781,000 aggregate principal amount of senior
unsecured notes previously issued on May 14, 2020 and (iii)
€2,517,066,000 aggregate principal amount of senior unsecured notes
previously issued on May 14, 2020, each issued pursuant to an
exemption from the registration requirements of the Securities Act
of 1933, as amended (the “Securities Act”), for an equal
principal amount of new notes in a transaction registered under the
Securities Act. A copy of the press release is attached hereto as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein in its entirety.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
ABBVIE INC. |
| |
|
|
Date:
November 18, 2020 |
By: |
/s/ Robert
A. Michael |
| |
Name: Robert
A. Michael |
| |
Title:
Executive Vice President, Chief Financial Officer |
|
Common Stock, $0.01 Par
Value |
ABBV |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Dec 2020 to Jan 2021
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jan 2020 to Jan 2021
